Email: cspc@cspc.cn
Email: cspc@cspc.cn
Global research System
Global Research System
We have a sound R&D system and a complete R&D chain, with highly professional teams engaged in areas ranging from drug discovery to clinical development, production transformation as well as intellectual property protection.
The needs of patients are at our heart
Members of Our R&D System
Five domestic and overseas R&D centres have been established with a large team of local and foreign high-level talents engaged in the development of innovative drugs.
JMT Bio
Shanghai JMT-Bio Inc., is a biopharmaceutical company engaged in the R&D of target tumor antigens and novel monoclonal antibodies for the immunotherapy of multiple types of cancers.
Zhongqi Pharmaceutical Technology (Shijiazhuang) Co. Ltd.
Zhongqi Pharmaceutical Technology (Shijiazhuang) Co. Ltd. has developed its astrengths in computer-aided drug design, liposome targeting agents and oral slow controlled release preparations.
CSPC Dophen Corporation
CSPC Dophen Corporation is a biopharmaceutical research company aiming to develop protein and antibody therapeutics. Its patented novel antibody-drug conjugation platform underlies its success in the submission of its first ADC-based IND application.
Conjupro Biotherapeutics, Inc.
Conjupro Biotherapeutics, Inc., is a leading biopharmaceutical company with a dedicated team of medical, regulatory and clinical experts. The company focuses on clinical research and drug development for treating Oncology, Cardiology, and CNS diseases.
NOVAROCK
NovaRock Biotherapeutics is an innovative and dynamic biotech company focusing on the development of antibody therapies for cancer and autoimmune diseases.
AlaMab
AlaMab is a clinical stage biopharmaceutical company focused on commercializing novel monoclonal antibody therapeutics to benefit patients suffering from indications with significant unmet treatment needs.
CSPC Megalith Biopharmaceutical Co.,Ltd
CSPC Megalith Biopharmaceutical Co.,Ltd. focuses on the R&D of oncology, immunology, digestive and metabolic drugs. The Company has established high-tech industrialization bases for three advantageous products including ADC drugs,monoclonal antibody drugs and mRNA vaccines.
